Alaunos Therapeutics, Inc. 8-K

What Happened
Alaunos Therapeutics, Inc. announced on Form 8-K that on December 17, 2025 it entered into a Settlement and Release Agreement with The University of Texas M.D. Anderson Cancer Center to resolve disputes over unpaid invoices under a 2019 Research and Development Agreement. Under the settlement, Alaunos agreed to pay MD Anderson a total of $285,055 in full satisfaction of the outstanding invoices, with the agreement documented as Exhibit 10.1 to the filing. The settlement includes mutual general releases of claims related to the unpaid invoices, subject to customary exceptions (including for breach of the Settlement Agreement and certain ongoing matters such as Protocol 2006-0676).

Key Details

• Total settlement amount: $285,055.
• Payment schedule: $142,528 due on or before December 30, 2025, then five monthly installments of $28,506 due on or before Jan 30, Feb 28, Mar 30, Apr 30 and May 30, 2026.
• Parties: Alaunos Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center.
• Agreement provides mutual releases of claims arising from or relating to the unpaid invoices, with customary exceptions and certain ongoing protocol matters excluded.

Why It Matters
The filing documents a concrete resolution of a past billing dispute and establishes a defined payment plan, eliminating uncertainty about these specific outstanding invoices. For investors, the settlement creates a known cash outflow schedule (Dec 2025–May 2026) totaling $285,055 and removes related claims between the parties subject to the stated exceptions. The full Settlement Agreement is filed as Exhibit 10.1 for review.